The Bladder Tumor Antigen (BTA) Stat Test and NMP22 BladderChek Test Compared to Voided Urine Cytology in the Detection of Bladder Cancer |
Du Yong Kim , Taek Sang Kim , Han Seok Kim , Byeong Ju Seong , Hyun Yul Rhew |
Department of Urology, Kosin University College of Medicine, Busan, Korea |
|
Abstract |
Purpose We assessed the sensitivity and specificity of the noninvasive BTA stat test and NMP22 BladderChek test for detection of bladder cancer with special reference to the grades and stages of the tumors. Materials and Methods: A total of 84 patients provided voided urine samples for the BTA stat test (BTA), NMP22 BladderChek test (NMP22) and cytopathologic study. The sensitivity and specificity of BTA and NMP22 were compared to those of standard voided urine cytology, and the sensitivities of these three tests were stratified according to histologic grades and stages. Results: Overall sensitivity of the BTA, NMP22 and urine cytology were 83.7%, 83.7% and 37.2%, specificity were 80.8%, 76.9% and 88.5% respectively. For each histologic grade of transitional cell carcinoma (low and high grade), sensitivity was 65.9% and 100% for BTA, and 69.5% and 100% for NMP22, and 17.4% and 60% for urine cytology, respectively. For each T-stage of transitional cell carcinoma (pTa, pT1, pT2-4), sensitivity was 42.9%, 87%, and 100% for BTA, and 42.9%, 87%, and 100% for NMP22, and 14.3%, 43.5%, and 38.5% for urine cytology, respectively. The false positive of BTA and NMP22 was seen in patients with gross hematuria, urinary tract infection, urologic malignancy other than bladder cancer and benign prostatic hyperplasia. Conclusions: BTA stat test, NMP22 BladderChek test are simple, non-invasive, adjunct to cystoscopy with urine cytology. In our study these tests were clinically reliable in the diagnosis and monitoring for bladder cancer with using of cystoscopy and urine cytology. (Korean J Urol Oncol 2007;5:97-101) |
Key Words:
Bladder cancer, Bladder tumor-associated antigen, NMP22, Cytology |
|